AI Test Predicts Who Benefits Most from Abiraterone

The test was trialled using biopsy images from men with high-risk prostate cancer that had not spread. Photograph: Lynne Cameron/PA

Date: 30 May 2025

Source: The Guardian

An AI-driven test can analyse tumour biopsy slides to identify which men with high-risk prostate cancer patients benefit most from the drug abiraterone. In trials, the test nearly halved 5-year mortality for biomarker-positive patients. This approach could reduce unnecessary treatment and save health systems millions.

Read